摘要
目的探讨沙库巴曲缬沙坦用于急性心肌梗死后二级预防的临床研究。方法选取我院2019年1月-2021年1月收治的60例急性心肌梗死患者,根据随机数字表法将其为对照组(n=31,予以厄贝沙坦治疗)和观察组(n=29,在对照组的基础上改予沙库巴曲缬沙坦治疗),观察两组临床疗效、心功能指标、心室重构指标、不良反应发生率及结局比较。结果治疗后,观察组总有效率(93.1%)高于对照组(67.73%)(P<0.05);两组左室舒张末期内径(LVDD)、左房内径(LVESD)均下降,且观察组低于对照组(P<0.05);左室射血分数(LVEF)上升,且观察组高于对照组(P<0.05);观察组不良反应发生率(17.24%)低于对照组(19.34%),无统计学意义(P>0.05);随访12个月,观察组再次住院率(6.89%)低于对照组(25.81%),有统计学意义(P<0.05),观察组不良反应发生率17.24%(5/29)稍低于对照组19.34%(6/31),有统计学意义(P<0.05)。结论沙库巴曲缬沙坦对于急性心肌梗死后二级预防患者的心功能改善和心室重构都有积极影响,同时可提高临床疗效,降低再次住院率和死亡率,且不良反应发生无差异。
Objective To investigate the clinical study of secondary prevention after acute myocardial infarction with sacubatrovalsartan.Methods 60 patients with acute myocardial infarction treated in our hospital from January 2019 to January 2021 were randomly divided into control group(n=31,treated with irbesartan)and observation group(n=29,treated with salkubatrol valsartan on the basis of the control group).The clinical efficacy,cardiac function index,ventricular remodeling index The incidence and outcome of adverse reactions were compared.Results After treatment,the total effective rate in the observation group(93.1%)was higher than that in the control group(67.73%)(P<0.05);The left ventricular end diastolic diameter(LVDD)and left atrial diameter(LVESD)decreased in the two groups,and the observation group was lower than that in the control group(P<0.05);The left ventricular ejection fraction(LVEF)in the observation group was higher than that in the control group(P<0.05);The incidence of adverse reactions in the observation group(17.24%)was lower than that in the control group(19.34%),which was not statistically significant(P>0.05);After 12 months of follow-up,the rehospitalization rate in the observation group(6.89%)was lower than that in the control group(25.81%),which was statistically significant(P<0.05).The incidence of adverse reactions in the observation group was 17.24%(5/29),which was slightly lower than that in the control group 19.34%(6/31),which was statistically significant(P<0.05).Conclusion Salkubatroxartan has a positive effect on the improvement of cardiac function and ventricular remodeling in patients with secondary prevention after acute myocardial infarction.At the same time,it can improve the clinical efficacy,reduce the rehospitalization rate and mortality,and there is no difference in the incidence of adverse reactions.
作者
钟耀彬
李汝秉
梁喜
杨伟民
何晓霞
周佩晓
ZHONG Yaobin;LI Rubing;LIANG Xi;YANG Weimin;HE Xiaoxia;ZHOU Peixiao(Department of Cardiology,Gaoyao District People's Hospital of Zhaoqing,Zhaoqing,Guangdong 526040)
出处
《智慧健康》
2022年第5期114-116,121,共4页
Smart Healthcare
基金
课题题目:沙库巴曲缬沙坦用于急性心肌梗死后二级预防的临床研究,课题编号:202004030729。
关键词
沙库巴曲缬沙坦
急性心肌梗死
二级预防
心功能
Sacubatrovalsartan
Acute myocardial infarction
Secondary prevention
Cardiac function
